Myocardial Infarction - Pipeline Insight, 2024

This “Myocardial Infarction - Pipeline Insight, 2024” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Myocardial Infarction pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Myocardial Infarction: Understanding

Myocardial Infarction: Overview

A myocardial infarction, commonly known as a heart attack, is the irreversible necrosis of heart muscle due to prolonged ischemia, usually caused by a blockage in the arteries that supply blood to the heart. If a healthcare provider doesn’t restore blood flow quickly, a heart attack can cause permanent heart damage and death. The lack of blood flow can occur because of many different factors but is usually related to a blockage in one or more of the coronary arteries. Treatment for a heart attack aims to restore blood flow to the affected heart muscle as soon as possible, and it can involve various methods, such as medication, percutaneous coronary intervention (PCI), and coronary artery bypass grafting. Several key factors affect the risk of having a heart attack, including family history, high blood pressure, high cholesterol, and smoking.

The symptoms of a heart attack can vary, but common symptoms include chest pain, discomfort, pain or discomfort in the jaw, neck, or back, shortness of breath, and nausea. It's important to seek emergency medical help if you experience any of these symptoms. Early and rapid electrocardiogram (ECG) testing is essential for diagnosis, with ECG being about 95% to 97% specific to myocardial infarction.

Lifestyle changes such as controlling high-fat, cholesterol, and salt diet, reducing alcohol consumption and smoking, regular exercise, weight control, blood pressure monitoring, stress reduction, and keeping aspirin for chest pain are recommended for prevention and management of myocardial infarction. The immediate treatment of MI includes taking aspirin, nitroglycerin, and oxygen. To prevent heart attacks, it's important to take earlier action to lower risks by controlling diet, fat, cholesterol, salt, smoking, nicotine, alcohol, and drugs. The treatment of MI also includes the use of thrombolytic or clot-dissolving drugs, painkillers, and antihypertensive drugs to lower blood pressure and improve the heart's oxygen demand.

“Myocardial Infarction - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Myocardial Infarction pipeline landscape is provided which includes the disease overview and Myocardial Infarction treatment guidelines. The assessment part of the report embraces, in depth Myocardial Infarction commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Myocardial Infarction collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Myocardial Infarction R&D. The therapies under development are focused on novel approaches to treat/improve Myocardial Infarction.

Myocardial Infarction Emerging Drugs Chapters

This segment of the Myocardial Infarction report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Myocardial Infarction Emerging Drugs

FDY 5301: Faraday PharmaceuticalsFDY-5301 is a patented, formulated, elemental reducing agent containing sodium iodide. It works to catalytically destroy hydrogen peroxide, which is naturally generated as a response to acute ischemia-reperfusion injury and contributes to loss of muscle mass and function. Preclinical studies of FDY-5301 have demonstrated its ability to reduce infarct size, improve cardiac function, and improve skeletal muscle function. Phase I data has demonstrated no signs of toxicity in healthy subjects. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Myocardial Infarction.

Zalunfiban: CeleCor TherapeuticsZalunfiban (RUC-4), a next generation GPI, is specifically designed to be administered subcutaneously to inhibit platelet aggregation for a first-point-of-medical contact treatment to improve outcomes for STEMI patients. Inhibiting platelet aggregation can slow or stop blood clot formation leading to coronary artery blockage, and in turn, can stop or prevent a heart attack. Zalunfiban targets platelet GPIIb/IIIa receptors, the final common pathway in platelet aggregation, to inhibit all platelet activators and can, under some conditions, promote recanalization of occluded arteries. In contrast, other antiplatelet medications, including P2Y12 inhibitors and aspirin, inhibit only one platelet activator and have not been demonstrated to promote recanalization. Further, due to decreased gastrointestinal absorption, oral P2Y12 inhibitors given before the procedure to open the artery do not act rapidly or reliably enough in STEMI patients during the crucial early minutes of a heart attack and have not demonstrated a clinical benefit to date. Currently, the drug is in Phase III stage of its clinical trial for the treatment of myocardial infarction.

MEDI6570: AstraZenecaMEDI6570, which AstraZeneca is developing, inhibits the LOX-1 receptor (anti-LOX-1 mAb). Blockade of the receptor reduced cytokine release via the NFkappaB pathway, inhibited monocyte adhesion, prohibited monocyte differentiation to foam cells and smooth muscle cell apoptosis, and improved endothelial function. MEDI6570 is suitable for post-MI patients with high residual risk attributed to inflammation via direct inhibition of multi-ligand scavenger receptor involved in oxidized LDL pathogenesis and inflammation. It is currently being investigated in the Phase II stage of development for the treatment of coronary heart disease.

RTP 026: ResoTher PharmaRTP-026 is developed as a new and innovative way to modulate the inflammatory response that occurs in the heart during the recovery phase of a myocardial infarction. Especially in the subset of patients showing high inflammatory activity, there is a need for novel treatments to reduce the risk of reinfarction and other major cardiovascular events. Upon formyl peptide type 2 receptor stimulation the RTP-026 compound induces a combination of anti-inflammatory and pre-resolving effects which in experimental models of myocardial infarction has profound effect not only on reducing the infarction size compared to placebo treatment, but importantly to restore cardiac function to a pre-infarction level. Currently, the drug is in Phase I stage of its clinical trial for the treatment of myocardial infraction.

Myocardial Infarction: Therapeutic Assessment

This segment of the report provides insights about the different Myocardial Infarction drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Myocardial Infarction

There are approx. 45+ key companies which are developing the therapies for Myocardial Infarction. The companies which have their Myocardial Infarction drug candidates in the most advanced stage, i.e. Phase III include, Faraday Pharmaceuticals.

Phases

This report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Myocardial Infarction pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Myocardial Infarction: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Myocardial Infarction therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Myocardial Infarction drugs.

Myocardial Infarction Report Insights

• Myocardial Infarction Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Myocardial Infarction Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Myocardial Infarction drugs?
• How many Myocardial Infarction drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Myocardial Infarction?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Myocardial Infarction therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Myocardial Infarction and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Novo Nordisk
• CeleCor Therapeutics
• Bayer
• Shanghai Zhongshan Hospital
• Takeda Pharmaceuticals
• Nexel
• Moleac Pte Ltd.
• LIB Therapeutics
• Windtree Therapeutics
• Faraday Pharmaceuticals
• CSL Behring
• Cardior Pharmaceuticals
• AstraZeneca
• R-Pharma
• Shilpa Biologicals

Key Products

• Ziltivekimab
• RUC-4 Compound
• Rivaroxaban
• Pirfenidone
• Pioglitazone
• NP-011
• MLC1501
• Lerodalcibep
• Istaroxime
• FDY-5301
• CSL300
• CDR132L
• AZD3366
• RPH-104
• SBDM 05

This product will be delivered within 4-6 business days.